Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

10171	Companies
209154	Keywords
139249	Articles
110866	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 07/23/2025 at 14:30, 8 months 15 days ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 8 months 30 days ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 8 months 30 days ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 8 months 30 days ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 10 months 24 days ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 10 months 24 days ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 10 months 24 days ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I
BRIEF

published on 04/09/2025 at 15:20, 11 months 28 days ago

Xenetic Biosciences Shares Promising Preclinical Data at SITC Meeting

Xenetic Biosciences Preclinical Data Solid Tumors DNase Technology CAR-T Cell Therapy
BRIEF

published on 04/09/2025 at 15:20, 11 months 28 days ago

Xenetic Biosciences partage des données précliniques prometteuses lors de la réunion du SITC

Biosciences Xénétiques Thérapie Cellulaire CAR-T Tumeurs Solides Données Précliniques Technologie DNase
PRESS RELEASE

published on 04/09/2025 at 15:15, 11 months 28 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette of Xenetic presents positive preclinical data on DNase I intervention enhancing CAR-T cell therapy in solid tumors at SITC 2025 Cell Therapy Meeting. Learn more at Xenetic's website

Immuno-oncology Xenetic DNase I SITC 2025 CAR-T Cell Therapy

Accesswire

Published on 04/08/2026 at 11:00, 56 minutes ago

Kingfisher Appoints Sharon G.K. Singh to Board of Directors
Published on 04/08/2026 at 08:05, 3 hours 51 minutes ago

Tocvan Announces Addition of Second Drill Rig and Accelerates High-Priority Drill Targets at Flagship Gran Pilar Gold-Silver Project
Published on 04/08/2026 at 02:50, 9 hours 6 minutes ago

Panther Minerals Announces Appointment of Rick Mah to Board of Directors
Published on 04/08/2026 at 01:35, 10 hours 21 minutes ago

Polaris Renewable Energy Announces Q1 2026 Investor Call Details
Published on 04/08/2026 at 00:40, 11 hours 16 minutes ago

Relevant Gold Announces Initial Closing of Strategic Financing

View all ACCESSWIRE

EQS Group

Published on 04/08/2026 at 11:40, 16 minutes ago

Semidynamics Secures a Strategic Investment to Advance Memory-Centric AI Inference Chips
Published on 04/08/2026 at 11:28, 28 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 04/08/2026 at 11:24, 32 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 04/08/2026 at 11:07, 49 minutes ago

SYNBIOTIC enters spring 2026 with operational progress, new regulatory momentum, and strong industry event presence
Published on 04/08/2026 at 11:05, 51 minutes ago

Hitachi Solutions Appoints Roger Lvin as Chief Executive Officer and President

Les Echos

Published on 04/08/2026 at 11:00, 56 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 04/08/2026 at 11:00, 56 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 04/08/2026 at 10:17, 1 hour 39 minutes ago

LA NOTE DE CREDIT LONG TERME BBB (PERSPECTIVE STABLE) ATTENDUE POUR EURAZEO DE LA PART DE S&P ET FITCH
Published on 04/08/2026 at 10:17, 1 hour 39 minutes ago

BBB LONG-TERM CREDIT RATING WITH A STABLE OUTLOOK EXPECTED FOR EURAZEO FROM BOTH S&P AND FITCH
Published on 04/08/2026 at 08:30, 3 hours 26 minutes ago

Edenred Mobility and Electra form a strategic partnership to accelerate the electrification of commercial fleets in France

View all LES ECHOS COMFI WIRE